Regarding PD-L1 expression levels and the clinical efficacy of EGFR-TKIs, Su et al., reported that strong PD-L1 expressions significantly lowered ORR, compared with the ORR of weak or negative PD-L1 expressions (35.7% versus 63.2% versus 67.3%, respectively, p = 0.002), while also shortening PFS (3.8 versus 6.0 versus 9.5 months, p < 0.001) in advanced NSCLC patients receiving EGFR-TKIs22. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.